Literature DB >> 2508325

Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin.

P E Williams1, P L Yap, J Gillon, R J Crawford, S J Urbaniak, G Galea.   

Abstract

Four patients (2 with X-linked, one with common variable hypogammaglobulinaemia, and 1 with ulcerative colitis) developed non-A, non-B hepatitis (NANBH) following administration of a specific batch of intravenous immunoglobulin (IV IgG) manufactured by the Scottish National Blood Transfusion Service using the pH4/mild pepsin method. Each patient had normal serum ALT levels over a preceding period of 12-67 months, with raised values developing within 4-18 weeks of first administration of the implicated batch. Two patients had very mild symptoms of hepatitis, the other 2 being asymptomatic. Over a follow-up period of 8-12 months, ALT levels returned to normal in 3 patients, but biopsy-proven chronic NANBH developed in the fourth. The level of NANBH virus in the starting plasma used to manufacture this batch may have exceeded the capacity of the process to inactivate the virus. The transmission of NANBH by one of approximately 110 batches administered demonstrates the importance of continued close surveillance of recipients of IV IgG, even if asymptomatic, by regular monitoring of liver function tests and recording of all batches received.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2508325     DOI: 10.1111/j.1423-0410.1989.tb04977.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  13 in total

Review 1.  New and old aspects of immunoglobulin application. The use of intravenous IgG as prophylaxis and for treatment of infections.

Authors:  L Hammarström; C I Smith
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

2.  Intravenous immunoglobulins.

Authors:  A D Webster
Journal:  BMJ       Date:  1991-08-17

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 4.  Intravenous immunoglobulin for secondary immunodeficiency.

Authors:  P L Yap
Journal:  Blut       Date:  1990-01

Review 5.  Human Immunoglobulins for intravenous use and hepatitis C viral transmission.

Authors:  H B Slade
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

6.  Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries.

Authors:  R A Williamson; R Burioni; P P Sanna; L J Partridge; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

Review 7.  Intravenous immune globulin in primary immunodeficiency.

Authors:  M Haeney
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Immunoglobulin preparations from hepatitis C antibody-positive plasma donors: influence on diagnosis and risk of infection in heart transplant recipients.

Authors:  W Prohaska; C Wolff; K Schlüter; W Köster-Eiserfunke; M M Körner; K Kleesiek
Journal:  Clin Investig       Date:  1992-07

9.  Failure to detect hepatitis C virus (HCV) genome by polymerase chain reaction in human anti-HCV-positive intravenous immunoglobulins.

Authors:  F Dammacco; D Sansonno; A Beardsley; E J Gowans
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin.

Authors:  S R Zuhrie; A D Webster; R Davies; A C Fay; T B Wallington
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.